- Home
- OPRA vs INBX Comparison
OPRA vs INBX Comparison
Compare OPRA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRA | INBX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | Norway | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | OPRA | INBX |
|---|---|---|
| Price | $19.29 | $93.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $21.50 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 335.1K | 331.5K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $21.29 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $11.71 | $20.55 |
| 52 Week High | $21.06 | $155.29 |
Technical Indicators
Market Signals| Indicator | OPRA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 44.79 |
| Support Level | $16.96 | $85.94 |
| Resistance Level | $19.43 | $96.12 |
| Average True Range (ATR) | 0.71 | 7.44 |
| MACD | -0.02 | 0.78 |
| Stochastic Oscillator | 51.41 | 33.00 |
Price Performance
Historical ComparisonAbout OPRA Opera Limited
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.